Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 2/20 | 0.35 |
| ▸ | TSHR | P16473 | 2/20 | 0.34 |
| ▸ | ATM | Q13315 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
| ▸ | DPP4 | P27487 | 4/20 | 0.31 |
| ▸ | DPP8 | Q6V1X1 | 2/20 | 0.31 |
| ▸ | DPP9 | Q86TI2 | 2/20 | 0.31 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | MMP2 | P08253 | 1/20 | 0.30 |
| ▸ | ANPEP | P15144 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13165476 | 0.81 | DPP4 (0.39) | MAPTGAATSHRATMPOLB | |
| SCHEMBL15099990 | 0.81 | DPP4 (0.39) | MAPTGAATSHRATMPOLB | |
| SCHEMBL21311703 | 0.79 | MAPT (0.34) | MAPTGAATSHRDPP4 | |
| SCHEMBL6627764 | 0.78 | LIPE (0.43) | MAPTGAATSHRATMPOLB | |
| SCHEMBL14145678 | 0.77 | — | — | |
| SCHEMBL220386 | 0.77 | — | — | |
| SCHEMBL23512793 | 0.75 | MAPT (0.38) | MAPTGAATSHRATMHPGD | |
| SCHEMBL24677876 | 0.74 | TSHR (0.54) | MAPTGAATSHRATMPOLB | |
| SCHEMBL29155482 | 0.73 | MAPT (0.45) | MAPTGAATSHRATMPOLB | |
| SCHEMBL29155481 | 0.73 | MAPT (0.45) | MAPTGAATSHRATMPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2018107109-A1 | NOVEL ANTI-KREMEN2 ANTIBODIES AND METHODS OF USE | ABBVIE STEMCENTRX LLC (US) | 2018-06-14 | — | — | WO | disclosed |
| WO-2017201442-A1 | ANTI-DLL3 DRUG CONJUGATES FOR TREATING TUMORS AT RISK OF NEUROENDOCRINE TRANSITION | ABBVIE STEMCENTRX LLC (US) | 2017-11-23 | — | — | WO | disclosed |